Skip to content

GH Axis · Reference monograph

Growth hormone-releasing peptide-6 (ghrelin-receptor agonist)

Reference compound — not available from Purity Peptides. Shown for research context.

Overview

GHRP-6 is one of the earliest synthetic growth hormone-releasing peptides, developed by Cyril Bowers and colleagues from structural work on modified enkephalins. Its ability to release growth hormone through a pathway independent of GHRH led to the search for a dedicated receptor, which was cloned in 1996 and later shown to be activated by the stomach hormone ghrelin.

Because of this history, GHRP-6 has been a reference ligand in much of the foundational research on the ghrelin system. Studies have documented strong GH release, marked stimulation of appetite and food intake, and, in animal models, cytoprotective effects on heart, liver and gut tissue that may involve receptors other than GHS-R1a. GHRP-6 was never developed into an approved medicine. It remains a useful pharmacological tool and is supplied here for research use only.

Mechanism studied

  1. GHRP-6
  2. GHS-R1a
  3. GH release & appetite
  4. IGF-1

GHRP-6 activates the ghrelin receptor GHS-R1a, which couples to Gq and phospholipase C to increase intracellular calcium in pituitary somatotrophs and hypothalamic neurons. This drives GH secretion and, through receptors in the arcuate nucleus, stimulates orexigenic NPY/AgRP neurons, explaining its pronounced effect on appetite and food intake in animal studies. Some in vitro studies and animal models.">preclinical work suggests GHRP-6 also binds the scavenger receptor CD36, a candidate pathway for the tissue-protective effects reported in ischaemia models.

Research highlights

  • 01Among the first synthetic GH-releasing peptides, predating ghrelin's discovery
  • 02Served as a reference ligand in cloning and characterising GHS-R1a
  • 03Pronounced appetite stimulation via hypothalamic ghrelin signalling
  • 04Cytoprotective effects reported in animal ischaemia and injury models
  • 05Prohibited in sport under WADA class S2

Latest published research

683 papers on PubMed →

  1. Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke

    Hernández-Bernal F et al. · Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2026 Oct · PMID 42462342

  2. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review

    Vasylieva V et al. · Sexual medicine reviews · 2026 Sep 30 · PMID 42862021

  3. Ghrelin Receptor Blockade Restricts Hepatic Echinococcus granulosus Infection by Suppressing Host Cell Proliferation and Enhancing Fibrotic Encapsulation

    Chen G et al. · Acta parasitologica · 2026 Sep 26 · PMID 42799941

  4. Ghrelin attenuates hypoxia-induced mitochondrial oxidative stress damage in HTR-8/SVneo trophoblasts

    Feng W et al. · Tissue & cell · 2026 Sep 10 · PMID 42753464

  5. A discovery-based proteomic approach of epidermal growth factor and growth hormone-releasing peptide-6 in a model of acute ischemic stroke

    Rodríguez-Ulloa A et al. · Pharmacological reports : PR · 2026 Aug · PMID 42258095

  6. EGF and GHRP6 Co-Administration Attenuates Cognitive Decline in Preclinical Models: Behavioral and Molecular Evidences

    Risco-Acevedo D et al. · Neurotoxicity research · 2026 Jul 4 · PMID 42399524

  7. Anterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report

    Perez SL et al. · Frontiers in surgery · 2026 · PMID 42465868

  8. Ghrelin impairs embryo development after ovarian hyperstimulation

    Ramírez ND et al. · The Journal of endocrinology · 2026 Jul 1 · PMID 42461148

Live feed from PubMed (NCBI) for “GHRP-6”, updated 2026-10-30. Listing a paper is not an endorsement of its findings.

Key references

  1. [1]Bowers, 1998 — Cell Mol Life Sci
  2. [2]PubMed — reviews on GHRP-6
  3. [3]WADA — Prohibited List of Substances and Methods

FAQ

  • GHRP-6 strongly activates ghrelin receptors in the hypothalamus, including those on NPY/AgRP neurons that drive feeding behaviour. Its pronounced orexigenic effect makes it a useful reference compound in studies of appetite regulation and the ghrelin system, alongside its role in GH-axis research.

  • Lyophilized GHRP-6 is normally kept sealed at −20 °C, protected from light and moisture. Once reconstituted for laboratory work, aliquots are held at 2–8 °C for short-term use or frozen, avoiding repeated freeze–thaw. Follow the lot-specific guidance on the certificate of analysis.

  • Every lot of GHRP-6 ships with a certificate of analysis reporting HPLC purity, mass-spectrometry identity against the expected molecular weight, appearance and lot number. Match the COA lot to the vial label and keep it with your experimental records.

FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.

Related compounds

WhatsApp